Table 1.
Characteristics of the HIV-1-infected participants according to their HTLV-2 and HCV co-infection status.
| HT+ Group | HT− Group | ANOVA | Student’s t-Test | |||
|---|---|---|---|---|---|---|
| HC+ Group | HCsvr Group | HC+ Group | HCsvr Group | 4 Groups | HT+ vs. HT− | |
| N | 41 | 25 | 25 | 37 | ||
| Age (years) | 44 (43–49) | 45 (42–48) | 47 (43–51) | 51 (47–52) | 0.001 | 0.001 |
| Gender (male) | 29 (70.7%) | 19 (76%) | 23 (92%) | 26 (70.3%) | 0.193 | 0.409 |
| Time of HIV-1 diagnosis (months) | 384 (343–415) | 371 (319–415) | 381 (353–410) | 389 (347–427) | 0.396 | 0.359 |
| Time on suppressive ART (months) | 186 (167–210) | 197 (171–221) | 196 (179–231) | 234 (222–281) | 0.071 | 0.034 |
| Pre-ART plasma HIV-1 RNA (log copies/mL) | 4.7 (4.2–5.2) | 4.7 (3.95–5) | 4.9 (4.7–5.3) | 4.8 (4.58–5.35) | 0.039 | 0.005 |
| Nadir CD4+ T cell count (cells/mm3) | 128 (67–189) | 160 (55–276) | 114 (44–164) | 114 (37–204) | 0.324 | 0.165 |
| CD4+ T cell count (cells/mm3) | 441 (297–574) | 502 (343–667) | 411 (214–542) | 649 (519–814) | 0.002 | 0.080 |
| Percentage | 21 (14–30) | 25 (22–32) | 20 (14–25) | 28 (24–37) | 0.001 | 0.316 |
| CD8+ T cell count (cells/mm3) | 954 (633–1410) | 925 (794–1011) | 872 (775–1280) | 814 (574–1107) | 0.584 | 0.605 |
| Percentage | 53 (40–59) | 45 (39–57) | 50 (40–56) | 40 (31–48) | 0.021 | 0.062 |
| CD4+/CD8+ ratio | 0.39 (0.26–0.69) | 0.61 (0.43–0.81) | 0.40 (0.28–0.63) | 0.74 (0.49–1.18) | 0.002 | 0.309 |
| Plasma HCV RNA (log copies/mL) | 6.11 (5.59–6.61) | Und | 6.43 (5.78–6.89) | Und | - | 0.481 |
HT+HC+ group, HTLV-2/HIV-1/HCV coinfected individuals; HT+HCsvr group, HTLV-2/HIV-1 coinfected individuals with sustained virological response after HCV treatment; HT−HC+ group, HIV-1/HCV coinfected individuals; HT−HCsvr, HIV-1 coinfected individuals with sustained virological response after HCV treatment; ART, antiretroviral treatment; Und, undetectable. Statistical significance in bold when p < 0.05. Median and interquartile range are shown.